Virax Biolabs Group Limited (VRAX)

GB — Healthcare Sector
Peers: BWV  REVB  HILS  KPRX  QNRX  NRBO  CDIO  ALLR  KRBP  BDRX  UNCY  PXMD 

Automate Your Wheel Strategy on VRAX

With Tiblio's Option Bot, you can configure your own wheel strategy including VRAX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol VRAX
  • Rev/Share 0.0274
  • Book/Share 2.7177
  • PB 0.3432
  • Debt/Equity 0.0698
  • CurrentRatio 11.5759
  • ROIC -0.7243

 

  • MktCap 4159594.0
  • FreeCF/Share -1.7487
  • PFCF -0.768
  • PE -0.4509
  • Debt/Assets 0.0639
  • DivYield 0
  • ROE -0.9393

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation VRAX H.C. Wainwright -- Buy -- $3 March 31, 2025

News

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy
VRAX
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral

Company Positioned to Support Public Health through Vaccine Efficacy Testing and Data-Driven Insights into Patients' Immune Profiles to Empower Informed Decisions on Vaccination LONDON , Feb. 25, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") believes that its technology aligns with the United States Department of Health and Human Services' commitment to prioritizing transparency on vaccine efficacy. This initiative is essential for empowering the public with the information needed to make informed health decisions.

Read More
image for news Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy

About Virax Biolabs Group Limited (VRAX)

  • IPO Date 2022-07-21
  • Website https://viraxbiolabs.com
  • Industry Biotechnology
  • CEO Mr. James Foster
  • Employees 17
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.